Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avillion LLP

http://avillionllp.com

Latest From Avillion LLP

MoonLake Takes SPAC Route To Challenge Novartis's Cosentyx

MoonLake of Switzerland is heading to the NASDAQ armed with $230m to take its tri-specific IL17A/IL-17F nanobody sonelokimab, acquired from Merck KGaA, into the highly competitive spaces of psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.

Financing Immune Disorders

AstraZeneca Eyes Opportunity To Transform Asthma Rescue Treatment

The company plans to file PT027, a new fixed-dose combination of albuterol and budesonide, in 2022 following two positive Phase III trials showing a benefit on lung function.

Respiratory Clinical Trials

Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

Deal Watch Business Strategies

Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi

Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.

Deal Watch Deals
See All

Company Information

  • Other Names / Subsidiaries
    • Avillion Group
    • Bond Avillion 2 Development LP
UsernamePublicRestriction

Register